News and Trends 5 Apr 2023
Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition
Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […]